Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Juluca is a prescription two-drug antiretroviral tablet containing dolutegravir and rilpivirine. It is used as a complete regimen in adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen for at least six months, have no history of treatment failure, and have no known resistance substitutions to either component.
read more about juluca ...Dolutegravir inhibits HIV integrase and blocks insertion of viral DNA into human DNA. Rilpivirine inhibits HIV-1 reverse transcriptase. The two actions interfere with separate steps in the viral replication cycle.
Juluca is used in adults with HIV-1 RNA below 50 copies per mL who have remained on a stable antiretroviral regimen for at least six months and meet the resistance and treatment-history criteria in current labeling. It replaces the prior antiretroviral regimen rather than being added to it.
The recommended dose is one tablet once daily with a meal. Each tablet contains 50 mg of dolutegravir and 25 mg of rilpivirine. If rifabutin is used at the same time, an additional 25 mg tablet of rilpivirine is taken once daily with Juluca and a meal for the duration of rifabutin treatment.
Serious concerns include severe hypersensitivity reactions, liver toxicity, depressive disorders, suicidal thoughts or behavior, and clinically significant drug interactions that can cause adverse reactions, loss of virologic response, or resistance. Dofetilide, proton pump inhibitors, and several strong enzyme-inducing medicines are contraindicated with Juluca.
Juluca is a complete HIV-1 treatment regimen for selected virologically suppressed adults switching from a stable antiretroviral regimen.
One tablet is taken once daily with a meal.
Each tablet contains 50 mg of dolutegravir and 25 mg of rilpivirine.
No. Proton pump inhibitors are contraindicated as they can lower rilpivirine exposure and cause loss of virologic response.
Dolutegravir and Rilpivirine: MedlinePlus Drug Information. https://www.medlineplus.gov/druginfo/meds/a624038.html. Date Accessed October 6, 2026.
Efficacy and Safety of Dolutegravir-Rilpivirine for Maintenance of Virological Suppression in Adults With HIV-1: 100-Week Data From the Randomised, Open-Label, Phase 3 SWORD-1 and SWORD-2 Studies. https://pubmed.ncbi.nlm.nih.gov/31307948/. Date Accessed October 6, 2026.
Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults With HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies. https://pubmed.ncbi.nlm.nih.gov/29310899/. Date Accessed October 6, 2026.
JULUCA (Dolutegravir and Rilpivirine) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=806653d1-bf35-4924-b999-ad5d21821cc1. Date Accessed October 6, 2026.
Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Characterization of the Dolutegravir/Rilpivirine Two-Drug Regimen in SWORD-1/-2 Phase 3 Studies. https://pubmed.ncbi.nlm.nih.gov/36740580/. Date Accessed October 6, 2026.